Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
| Sponsored by: | Burzynski Research Institute |
| Information provided: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003508 |
Purpose:
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with advanced mesothelioma.
| Condition | Intervention | Phase |
|
Malignant Mesothelioma |
Drug: antineoplaston A10 Drug: antineoplaston AS2-1 |
Phase 2 |
Eligibility
Study Design: Primary Purpose: Treatment
Official Title: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma
Enrollment Size: Both
Gender: 1 Year
Min. Age: N/A
Max. Age: No
Location and Contact Information
United States, Texas
Burzynski Clinic, Houston, Texas, 77055-6330, United States
Status:
Last modified: July 29 2010.
